Ten (10) PhD Positions, University of Aberdeen, UK (2016-2017)

Marie Skłodowska-Curie ITN-ETN PET3D-programme in “PET imaging in Drug Design and Development” comprises a total of 15 cutting edge research projects in three main therapeutic areas of oncology, cardiovascular and central nervous system at eight beneficiary institutions, providing research and training in the field of drug design and health. PET imaging has the potential to revolutionize drug design and development by providing reliable answers at a much earlier stage of drug development to key questions emerging during the disease care cycle, thus facilitating effective transition from pre-clinical to clinical phase in drug development. 6 academic and 2 non-academic beneficiaries will provide a unique training opportunity that will transfer key multidisciplinary and industry-relevant skills to 10 highly motivated Early Stage Researchers (ESRs). Beneficiaries: UK – University of Aberdeen UK – Coordinating University- (Graduate School in Life Sciences and Medicine); The Netherlands – Stichting VU-VUMC; Belgium – Vrije Universiteit Brussel; Spain – Asociación – CIC biomaGUNE; Germany – Westfaelische Wilhelms-Universitaet Muenster;UK – Imanova Limited; Sweden – AstraZeneca plc. 5 further ESR positions will be available in 3-6 months time.

You must satisfy the eligibility requirements for an ESR under the European Commission Horizon 2020 Early Stage Training Scheme. (1) ESR requirement: you should have less than four years research experience and you must not possess a PhD. This 4 year period is measured from the date of obtaining the degree which would formally entitle to embark on a doctorate. (2) Mobility requirement: you must not have resided or carried out your main activity (work, studies, etc.) in the country to which you are applying for more than twelve months in the three years immediately prior to your recruitment.

For more information, please visit:
http:///www.nature.com